Application of Radiomics in Precise Preoperative Diagnosis and Prognsis Evaluation of Colorectal Cancer.
NCT ID: NCT03787667
Last Updated: 2018-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2000 participants
OBSERVATIONAL
2018-05-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with pathologically diagnosed colorectal cancer
Patients with pathologically diagnosed colorectal cancer
CT or MRI based Radiomics
Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT or MRI based Radiomics
Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female aged 18-75 years old on the day of signing informed consent.
* Patients who received imageological examination of primary or metastasis
* Patients who received surgical resection of primary or metastasis
* Patients must have a performance status of ≤1 on the ECOG Performance Scale.
* Colorectal cancer is the only malignant tumor
* Written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study
Exclusion Criteria
* Tis stage patients
* Paitents who diagnosed with malignant disease within 5 years.
* Patients with a history or current evidence of any condition or abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the Investigator.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guoxiang Cai
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Guoxiang Cai
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ColoRadiomics
Identifier Type: -
Identifier Source: org_study_id